Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Organisation › Details

Apeiron Biologics Forschungs- und Entwicklungs GmbH

Apeiron is a mainly privately financed biotech company based in Vienna, Austria, developing immunologic and biologic therapies against cancer. Its portfolio consists of five clinical projects and some preclinical approaches. Its lead project, APN311, is currently being investigated in high-risk neuroblastoma, together with the internationally active SIOPEN study group, with more than 600 patients having received treatment to date. Apeiron's project APN301 is an anti-GD2 antibody-IL2 fusion protein which is currently in a phase II trial in the US and Canada in neuroblastoma and in a separate trial in melanoma. The recombinant human Angiotensin Converting Enzyme 2 (GSK2586881, formerly APN01) was developed by Apeiron until end of Phase I, licensed to GlaxoSmithKline (GSK) in 2010 and is presently being investigated by GSK in an ongoing phase II study in Acute Lung Injury. Furthermore, a program is ongoing to develop therapies to selectively boost the immune system to efficiently combat cancer (APN401: individualized cellular therapy; APN411: low molecular weight compound, in collaboration with Evotec). APN201 (human Superoxide Dismutase) is pursued to cope with oxidative stress and associated inflammation. *

 

Period Start 2005-09-01 start
Period End 2010-02-04 renamed before
  Group Apeiron (Group)
  Today Apeiron Biologics AG
  Predecessor IMBA – Institute of Molecular Biotechnology GmbH
  Successor Apeiron Biologics AG
Product Industry BIOTECH
Person Person Penninger, Josef (IMBA + Uni Toronto + Uni Wien 200502)
     
Region Region Wien (Vienna)
  Country Austria
  Street 59 Brunner Str.
  City 1230 Wien
  Tel +43-1-865-6577
    Address record changed: 2008-12-15
     
Basic data Employees A: 1 to 10 (2008-02-11)
     
    * Document for �About Section�: Apeiron Biologics AG. (1/9/14). "Press Release: Apeiron Signs Regional License Agreements for the Commercialization of Its Neuroblastoma Therapy". Vienna.
     
   
Record changed: 2017-04-01

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

More documents for Apeiron (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top